ArticleBMC cardiovascular disorders2025
Association between serum uric acid and cardiometabolic syndrome: a cross-sectional study from NHANES 1999-2020.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsThe relationship between serum uric acid (SUA) levels and cardiometabolic syndrome (CMS) remains controversial. This study aims to investigate the association between SUA and CMS in a large, nationally representative US population.
methodsThis cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020. Logistic regression models were used to evaluate the association between SUA and CMS, while restricted cubic spline analysis explored the dose-response relationship. Subgroup analyses were conducted to examine effect modifications by demographic and socioeconomic factors.
resultsThe study included 12,638 participants. After adjusting for multiple confounders, higher SUA levels were significantly associated with increased odds of CMS (OR: 1.37, 95% CI: 1.31-1.42). This association remained consistent across different SUA quartiles, with the highest quartile showing the strongest association (OR: 2.72, 95% CI: 2.34-3.16). Restricted cubic spline analysis revealed a nonlinear dose-response relationship between SUA and CMS. Subgroup analyses showed that the association was stronger in females (OR: 1.78, 95% CI: 1.69-1.87) compared to males (OR: 1.47, 95% CI: 1.41-1.54), and varied across education levels and racial/ethnic groups.
conclusionOur findings indicate a significant positive association between SUA levels and CMS in the US adult population. This relationship appears to be linear and is influenced by factors such as sex, education level, and race/ethnicity. These results suggest that SUA levels may be a useful marker for CMS assessment and potential intervention strategies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.